GENFIT Secures Medicare Coverage for NASHnext®, Expanding U.S. Diagnostic Market
Event summary
- GENFIT's NASHnext® diagnostic test secured Medicare coverage, effective August 10, 2026.
- The test will be reimbursed at approximately $252 per test under the Clinical Laboratory Fee Schedule.
- NASHnext® is licensed to Labcorp and targets high-risk patients with metabolic diseases like prediabetes and obesity.
- GENFIT plans to host an analyst event this fall to discuss MASH diagnostics further.
The big picture
GENFIT's Medicare coverage for NASHnext® positions the company to capitalize on the growing U.S. MASH diagnostic market, where early identification of at-risk patients is critical. With the first MASH therapy already achieving near-blockbuster status and additional agents in development, non-invasive diagnostics like NASHnext® are becoming essential tools for clinicians. This milestone also strengthens GENFIT's second revenue stream beyond its therapeutic portfolio.
What we're watching
- Market Adoption
- The pace at which private insurers adopt NASHnext® coverage following Medicare's decision.
- Revenue Growth
- Whether GENFIT can sustain significant recurring revenue from Labcorp's commercialization of the test.
- Competitive Positioning
- How NASHnext® differentiates itself in a rapidly expanding U.S. MASH market with new therapies emerging.
Related topics